Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$12.59 - $18.8 $15.1 Million - $22.5 Million
1,195,453 Added 88.14%
2,551,703 $44.6 Million
Q1 2022

May 16, 2022

BUY
$12.02 - $16.69 $10.3 Million - $14.3 Million
856,250 Added 171.25%
1,356,250 $22.2 Million
Q4 2021

Feb 14, 2022

BUY
$10.69 - $16.83 $5.35 Million - $8.42 Million
500,000 New
500,000 $8.16 Million

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.